Safety of concomitant tamoxifen and warfarin

Annals of Pharmacotherapy

Volumn 43, Issue 11, 2009, Pages 1867-1871

  Givens, Carrie B ^a   Bullock, Laura N ^a,b   Franks, Andrea S ^c  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Drug interaction; Tamoxifen; Warfarin

Indexed keywords

COTRIMOXAZOLE; CYTOCHROME P450 2C; DOXORUBICIN; OMEPRAZOLE; TAMOXIFEN; VITAMIN K GROUP; WARFARIN;

ABDOMINAL PAIN; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; HEMATEMESIS; HEMATOMA; HEMATURIA; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MEDLINE; NEOPLASM; PRESCRIPTION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; SUBDURAL HEMATOMA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; TAMOXIFEN; WARFARIN;

EID: 70449698478     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M176     Document Type: Review

References (24)

1. Ansell J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(suppl):160S-98S. DOI 10.1378/chest.08-0670
2. Widermann CJ, Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res 2008;122(suppl): S13-8. DOI 10.1016/S0049-3848(08)70004-5 (Pubitemid 351783319)
3. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78:133-136
4. Osborn CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618 DOI 10.1056/NEJM199811263392207
5. Product information. Nolvadex (tamoxifen). Wilmington, DE: AstraZeneca Pharmaceuticals LP, May 2002.
6. Tamoxifen. In: Klasco RK, ed. DRUGDEX System (electronic version). Greenwood Village, CO: Thomson Micromedex (accessed 2009 Apr 21).
7. Warfarin. In: Klasco RK, ed. DRUGDEX System (electronic version). Greenwood Village, CO: Thomson Micromedex (accessed 2009 Apr 21).
8. Lacy CF, Armstrong LL, Goldman M P, Lance LL. Warfarin and tamoxifen. In: Drug information handbook: a comprehensive resource for all clinicians and healthcare professionals. 14th ed. Hudson, OH: Lexicomp Inc., 2006:1512- 4, 1667-1670
9. Lodwick R, McConkey B, Brown AM, Beeley L. Life threatening interaction between tamoxifen and warfarin (letter). Br Med J 1987;295: 1141. DOI 10.1136/bmj.295.6606.1141-b (Pubitemid 17151289)
10. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin (letter). Br Med J 1989;298:93. DOI 10.1136/bmj.298.6666. 93 (Pubitemid 19032933)
11. Ritchie LD, Grant SMT. Tamoxifen - warfarin interaction: the Aberdeen hospitals drug file (letter). Br Med J 1989;298:1253. DOI 10.1136/bmj.298.6682. 1253
12. Jönsson AK, Spigset O, Jacobsson I, Hagg S. Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions. Pharmacoepidemiol Drug Saf 2007;16:309-15. DOI 10.1002/pds 1291 (Pubitemid 46431693)
13. World Health Organization. The use of the WHO-UMC system for standardized case causality assessment. www.who-umc.org/graphics/4409. pdf (accessed 2009 Aug 21).
14. Mishra D, Paudel R, Kishore PV, Palaian S, Bista D, Mishra P. Interaction between warfarin and tamoxifen: a case report. Kathmandu Univ Med J 2007;5:105-107
15. Boruban MC, Yasar U, Babaoglu MO, Bozkurt SO. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients (abstract). J Chemother 2006;18:421-424 (Pubitemid 44450025)
16. Chen J, Hage DS. Quantitative studies of allosteric effects by biointeraction chromatography: analysis of protein binding for low-solubility drugs. Anal Chem 2006;78:2672-2683 DOI 10.1021/ac052017b
17. Barlas AH. Acquired factor VIII deficiency in an elderly woman on tamoxifen. J Am Geriatr Soc 1986;34:318-320
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
19. Schulman S, Beyth RJ, Kearon C, Levin MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment, American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008;133(suppl):257S-98S. DOI 10.147/chest.08-0674
20. Byrd DC, Gaskins SE, Parrish AM, Freeman LB. Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract 1999;12:486-488
21. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother 2002;36:1554-1557 DOI 10.1345/aph.1C074
22. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother 2008;6:33-36 DOI 10.1016/j.amjopharm.2008.03.003
23. Seto AC, Kenyon K, Wittkowsky AK. Discrepancies in identification of major bleeding events in patients taking warfarin. Pharmacotherapy 2008;28:1098-1103 DOI 10.1592/phco.28.9.1098
24. Landefield CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989;42: 711-718 DOI 10.1016/0895-4356(89)90066-8